Recognising the importance of chronic lung disease: a consensus statement from the Global Alliance for Chronic Diseases (Lung Diseases group)
Invalid Access Key! Invalid Access Key!
Featured Post
Respirology | APSR Respiratory Medicine Journal
AI Software May Successfully Diagnose Tuberculosis - UPI.com
Artificial intelligence (AI) may help clinicians diagnose tuberculosis in parts of the world where radiologists are scarce, a new study suggests.
AI software successfully identified tuberculosis (TB) from cellphone photos of chest X-ray images, researchers reported at a European conference this week.
"We've shown that AI software is at least as good at detecting TB as a trained radiologist and that a simple mobile phone photograph is sufficient for analysis," said study leader Dr. Frauke Rudolf, of the infectious diseases department at Aarhus University Hospital, in Denmark.
Chest X-rays play an important role in detecting TB in patients unable to produce good quality sputum (phlegm) samples for microbiological analysis. Using software to help diagnose conditions based on the X-rays could help in areas with limited resources and few radiologists.
Rudolf's team set out to determine the accuracy of this method. They compared the performance of AI software in assessing chest X-rays with that of two Ethiopian radiologists with different levels of experience.
The AI was given mobile phone photographs of non-digital chest X-rays.
Among 498 patients, 11% had been diagnosed with TB, 41 clinically and 16 through PCR tests, the study authors noted.
The software was as good or better than a trained radiologist at identifying the PCR-confirmed cases. It correctly identified 75% of all PCR-confirmed cases and about 86% of non-TB cases.
By comparison, the less-experienced radiologist's assessments correctly picked up about 63% of the PCR-confirmed cases and correctly identified nearly 92% of those who didn't have TB.
The experienced radiologist correctly chose 75% of the PCR-confirmed cases and 82% of those that didn't have TB.
"With an estimated 3 million undiagnosed patients in 2021, there is an urgent need to develop novel strategies and technologies aimed at improving TB detection in low-resource, high-incidence settings," Rudolf said in a news release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
TB is a major cause of death and disease worldwide, killing 1.6 million people each year. It is the 13th leading cause of death globally and the second biggest infectious killer, after COVID-19.
"In low-resource areas with a high incidence of TB but a shortage of radiologists, chest X-rays could be photographed with a mobile phone and the image sent to be analyzed remotely by the AI," Rudolf said. "This would allow more chest X-rays to be read properly and, crucially, allow more cases of TB to be diagnosed."
The study was scheduled for presentation Monday at the ECCMID, in Denmark. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
The U.S. Centers for Disease Control and Prevention has more on tuberculosis.
Copyright © 2023 HealthDay. All rights reserved.
Chest X-ray Aids In Early Diagnosis Of Children Exposed To TB
November 16, 2022
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.Back to Healio
In children exposed to tuberculosis, chest radiography helped in detecting asymptomatic coprevalent TB and predicting incident TB after baseline, according to a study in American Journal of Respiratory and Critical Care Medicine.
Further, isoniazid preventive therapy (IPT) was 82% effective in preventing a future diagnosis of incident TB in asymptomatic children with abnormal chest radiographs, according to researchers.
The study's primary outcomes included coprevalent TB, or TB that presented at the beginning of the study, and incident TB, or TB diagnosed within a 1-year follow-up period among children without initial coprevalent TB. Source: Adobe Stock
"The clinical management of TB-exposed children involves two different decision points," Chuan-Chin Huang, ScD, professor in the department of global health and social medicine at Harvard Medical School, and colleagues wrote. "First, making a definitive diagnosis of TB disease in children is challenging because they are much less likely than adults to have microbiologically confirmed disease, and it is, therefore, necessary to rely on 'clinical diagnosis' using a combination of findings from history, physical exam, radiologic imaging, and TB immune-based testing (eg, tuberculin skin test [TST] and interferon-g release assays), all of which have their limitations.
"Second, clinicians are often reluctant to initiate [TB preventive therapy] for TB infection in children with clinical or radiologic abnormalities compatible with intrathoracic TB (but for which they have low suspicion that TB is indeed the etiology) because of the concern that a child with undetected TB disease who is inadvertently treated with preventive monotherapy might develop drug resistance," Huang and colleagues added.
In a longitudinal cohort study, Huang and colleagues evaluated 4,452 children from September 2009 to August 2012 in Lima, Peru who were exposed to TB through household contacts to observe the diagnostic and prognostic characteristics of chest radiography in this patient population.
Researchers additionally sought to understand the protective efficacy of IPT in children who had abnormal chest radiographs. Clinicians screened the children by TST, symptom assessment and chest radiography.
The study's primary outcomes included coprevalent TB, or TB that presented at the beginning of the study, and incident TB, or TB diagnosed within a 1-year follow-up period among children without initial coprevalent TB.
Of the 4,448 children screened for TB symptoms, 908 (20%) had positive results. Further, 1,124 of the 4,280 children (25%) screened by TST were positive.
Additionally, 1,012 (23%) children underwent chest radiography, of which 79 (2%) came back abnormal, and 2,320 (54%) children received IPT.
Overall, 95 children were diagnosed with coprevalent TB.
Researchers observed that those with TB symptoms had a 4.71 (95% CI, 2.93-7.59) higher likelihood to be diagnosed with coprevalent TB than asymptomatic children.
Coprevalent TB also appeared more likely in symptomatic vs. Asymptomatic children with normal chest radiographs (adjusted RR = 4.21; 95% CI, 1.28-13.86), according to researchers.
Among those with abnormal radiographs, researchers found that coprevalent TB was 25.06 (95% CI, 1.02-613.76) times more likely among asymptomatic children and 34.23 (95% CI, 7.58-154.68) times more likely among symptomatic children.
In terms of incident TB, 95 children were diagnosed during 1-year follow-up.
Incident TB diagnosis appeared more common among children who had abnormal chest radiographs and who were asymptomatic (adjusted HR = 26.71; 95% CI, 10.44-68.3), as well as symptomatic (aHR = 25.94; 95% CI, 4.1-164.28), compared with children with normal chest X-rays and no symptoms.
IPT showed 82% efficacy in the children who were asymptomatic and had an abnormal chest radiography (aHR = 0.18; 95% CI, 0.04-0.95).
Among children with TB symptoms and normal chest radiography, researchers found that two of the five (40%) children not given IPT developed incident TB compared with none of the seven children given IPT.
Additionally, of the 35 children who had a positive TST and abnormal chest radiography, researchers found that 28 of their radiography results did not suggest TB. IPT was found to be 93% effective in this subgroup, as eight out of 14 children not receiving IPT developed incident TB compared with only one child of 14 who received IPT.
Overall, of 46 asymptomatic children who had an abnormal chest X-ray at enrollment, 28 were diagnosed with coprevalent or incident TB.
"Our study suggests that the addition of radiography for child TB contacts may not only allow for TB diagnosis earlier than would be accomplished through symptom screening alone but may also identify a subgroup of child contacts at high risk of later TB progression," Huang and colleagues wrote. "We also show that nonspecific [chest radiography] findings in child TB contacts may indicate incipient or subclinical TB disease that requires formal treatment. However, access to tuberculosis preventive therapy should not be constrained because it remains highly effective in asymptomatic contacts, even in those with [chest radiography] abnormalities."
This study by Huang and colleagues adds to the literature indicating the importance of child TB prevention and the need for solid evidence in older children/adolescents who are diagnosed with TB, according to an accompanying editorial by Ben J. Marais, MD, PhD, professor at The University of Sydney Children's Hospital at Westmead Clinical School, and Stephen M. Graham, MD, PhD, professor of international child health at the University of Melbourne.
"Closing persistent gaps in child TB prevention and detection is essential to meet targets formulated at the United Nations high-level meeting on the fight against TB," Marais and Graham wrote. "In the end, [TB preventive treatment] implementation and scale-up will only be achieved if it is perceived as a priority by TB programs and major donors, as demonstrated by the high [TB prevention treatment] coverage in HIV programs. This will require practical implementation plans, reliable drug supply and effective monitoring and evaluation systems."
Reference:Marais BJ, et al. Am J Respir Crit Care Med. 2022; doi:10.1164/rccm.202205-1023ED.
Sources/DisclosuresCollapse Disclosures: Huang reports receiving a grant from the National Institute of Allergy and Infectious Diseases. Please see the study for all other authors' relevant financial disclosures. Marais and Graham report no relevant financial disclosures.Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.Back to Healio
Advancing Host-directed Therapy For Tuberculosis - Nature
Gillespie, S. H. Et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577–1587 (2014).
Merle, C. S. Et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588–1598 (2014).
Jindani, A. Et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599–1608 (2014).
Churchyard, G. J. Et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N. Engl. J. Med. 370, 301–310 (2014).
Pasipanodya, J. G. Et al. Pulmonary impairment after tuberculosis and its contribution to TB burden. BMC Public Health 10, 259 (2010).
Alling, D. W. & Bosworth, E. B. The after-history of pulmonary tuberculosis. VI. The first fifteen years following diagnosis. Am. Rev. Respir. Dis. 81, 839–849 (1960).
Mortaz, E. Et al. Interaction of pattern recognition receptors with Mycobacterium tuberculosis. J. Clin. Immunol. 35, 1–10 (2015).
Guirado, E., Schlesinger, L. S. & Kaplan, G. Macrophages in tuberculosis: friend or foe. Semin. Immunopathol. 35, 563–583 (2013).
Tan, B. H. Et al. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J. Immunol. 177, 1864–1871 (2006).
Gopal, R. Et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am. J. Respir. Crit. Care Med. 188, 1137–1146 (2013).
Ma, N. Et al. Clinical and epidemiological characteristics of individuals resistant to M. Tuberculosis infection in a longitudinal TB household contact study in Kampala, Uganda. BMC Infect. Dis. 14, 352 (2014).
Subbian, S. Et al. Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits. Cell Commun. Signal. 11, 60 (2013).
Kristensen, I. A., Veirum, J. E., Moller, B. K. & Christiansen, M. Novel STAT1 alleles in a patient with impaired resistance to mycobacteria. J. Clin. Immunol. 31, 265–271 (2011).
Newport, M. J. Et al. A mutation in the interferon-γ-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941–1949 (1996).
Tena, G. N. Et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus, and its relationship to T cell function. J. Infect. Dis. 187, 1544–1551 (2003).
Fletcher, H. A. Et al. Inhibition of mycobacterial growth in vitro is enhanced following primary BCG vaccination but not BCG revaccination of human subjects. Clin. Vaccine Immunol. 20, 1683–1689 (2013).
Chao, M. C. & Rubin, E. J. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 64, 293–311 (2010).
Majumdar, S. D. Et al. Appropriate DevR (DosR)-mediated signaling determines transcriptional response, hypoxic viability and virulence of Mycobacterium tuberculosis. PLoS ONE 7, e35847 (2012).
Hoger, S., Miller, T., Katz, D., Beavers, S. & Lykens, K. Longevity loss among cured tuberculosis patients and the potential value of prevention. Int. J. Tuberc. Lung Dis. 18, 1347–1352 (2014).
Banu Rekha, V. V. Et al. Assessment of long term status of sputum positive pulmonary TB patients successfully treated with short course chemotherapy. Indian J. Tuberc. 56, 132–140 (2009).
Briken, V., Porcelli, S. A., Besra, G. S. & Kremer, L. Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol. Microbiol. 53, 391–403 (2004).
Gutierrez, M. G. Et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119, 753–766 (2004).
Fabri, M., Realegeno, S. E., Jo, E. K. & Modlin, R. L. Role of autophagy in the host response to microbial infection and potential for therapy. Curr. Opin. Immunol. 23, 65–70 (2011).
Watson, R. O., Manzanillo, P. S. & Cox, J. S. Extracellular M. Tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 150, 803–815 (2012).
Renna, M. Et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Invest. 121, 3554–3563 (2011).
Ravikumar, B. Et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genet. 36, 585–595 (2004).
Gao, P. Et al. Structure–function analysis of STING activation by c[G(2′,5′)pA(3′,5′)p] and targeting by antiviral DMXAA. Cell 154, 748–762 (2013).
Tijono, S. M. Et al. Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Br. J. Cancer 108, 1306–1315 (2013).
Shoji-Kawata, S. Et al. Identification of a candidate therapeutic autophagy-inducing peptide. Nature 494, 201–206 (2013).
Stanley, S. A. Et al. Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth. PLoS Pathog. 10, e1003946 (2014).
Bruns, H. Et al. Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages. J. Immunol. 189, 4069–4078 (2012).
Napier, R. J. Et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10, 475–485 (2011).
Yogalingam, G. & Pendergast, A. M. Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J. Biol. Chem. 283, 35941–35953 (2008).
Gotta, V. Et al. Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions. Leuk. Res. 38, 764–772 (2014).
Ogolla, P. S. Et al. The protein kinase double-stranded RNA-dependent (PKR) enhances protection against disease cause by a non-viral pathogen. PLoS Pathog. 9, e1003557 (2013).
Wu, K. Et al. Improved control of tuberculosis and activation of macrophages in mice lacking protein kinase R. PLoS ONE 7, e30512 (2012).
Martineau, A. R. Et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc. Natl Acad. Sci. USA 108, 19013–19017 (2011).
Liu, P. T. Et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770–1773 (2006).
Wejse, C. Et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 179, 843–850 (2009).
Nursyam, E. W., Amin, Z. & Rumende, C. M. The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med. Indones. 38, 3–5 (2006).
Ralph, A. P. Et al. L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial. PLoS ONE 8, e70032 (2013).
Martineau, A. R. Et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 377, 242–250 (2011).
Coussens, A. K. Et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc. Natl Acad. Sci. USA 109, 15449–15454 (2012).
Karyadi, E. Et al. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am. J. Clin. Nutr. 75, 720–727 (2002).
Gondcaille, C. Et al. Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J. Cell Biol. 169, 93–104 (2005).
Steinmann, J., Halldorsson, S., Agerberth, B. & Gudmundsson, G. H. Phenylbutyrate induces antimicrobial peptide expression. Antimicrob. Agents Chemother. 53, 5127–5133 (2009).
van der Does, A. M., Kenne, E., Koppelaar, E., Agerberth, B. & Lindbom, L. Vitamin D3 and phenylbutyrate promote development of a human dendritic cell subset displaying enhanced antimicrobial properties. J. Leukoc. Biol. 95, 883–891 (2014).
Mily, A. Et al. Oral intake of phenylbutyrate with or without vitamin D3 upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis. BMC Pulm. Med. 13, 23 (2013).
Raqib, R. Et al. Clinical trial of oral phenylbutyrate and vitamin D adjunctive therapy in pulmonary tuberculosis in Bangladesh. Int. J. Tuberc. Lung Dis. 18, S233–S234 (2014).
Egan, D. F. Et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456–461 (2011).
Arai, M. Et al. Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro. J. Pharmacol. Exp. Ther. 334, 206–213 (2010).
Singhal, A. Et al. Metformin as adjunct anti-tuberculosis therapy. Sci. Transl Med. 6, 263ra159 (2014).
Dawson, R. Et al. Immunomodulation with recombinant interferon-γ1b in pulmonary tuberculosis. PLoS ONE 4, e6984 (2009).
Johnson, J. L. Et al. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168, 185–191 (2003).
Achkar, J. M. & Casadevall, A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13, 250–262 (2013).
Roy, E. Et al. Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect. Immun. 73, 6101–6109 (2005).
Dooley, D. P., Carpenter, J. L. & Rademacher, S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin. Infect. Dis. 25, 872–887 (1997).
Critchley, J. A., Young, F., Orton, L. & Garner, P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 13, 223–237 (2013).
Tobin, D. M. Et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434–446 (2012).
Wallis, R. S. Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis. Open Forum Infect. Dis. Http://dx.Doi.Org/10.1093/ofid/ofu020 (2014).
Wallis, R. S., Wang, C., Meyer, D. & Thomas, N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS ONE 8, e71116 (2013).
Johnson, J. R., Taylor, B. C., Morrissey, J. F., Jenne, J. W. & McDonald, F. M. Corticosteroids in pulmonary tuberculosis. I. Over-all results in Madison–Minneapolis veterans administration hospitals steroid study. Am. Rev. Respir. Dis. 92, 376–391 (1965).
Mayanja-Kizza, H. Et al. Immunoadjuvant therapy for HIV-associated tuberculosis with prednisolone: a phase II clinical trial in Uganda. J. Infect. Dis. 191, 856–865 (2005).
Tripathy, S. P. Et al. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 64, 73–91 (1983).
Keane, J. Et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. 345, 1098–1104 (2001).
Van, A. G., Vermeire, S. & Rutgeerts, P. The potential for disease modification in Crohn's disease. Nature Rev. Gastroenterol. Hepatol. 7, 79–85 (2010).
Keystone, E. C. Et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400–1411 (2004).
Wallis, R. S. Et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18, 257–264 (2004).
Sandborn, W. J. Et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121, 1088–1094 (2001).
Utz, J. P. Et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124, 177–185 (2003).
Wallis, R. S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum. 58, 947–952 (2008).
Wallis, R. S., Broder, M. S., Wong, J. Y. & Beenhouwer, D. O. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin. Infect. Dis. 39, 1254–1256 (2004).
Jick, S. S., Lieberman, E. S., Rahman, M. U. & Choi, H. K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 55, 19–26 (2006).
Carmona, L. Et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52, 1766–1772 (2005).
Tubach, F. Et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 60, 1884–1894 (2009).
Blackmore, T. K., Manning, L., Taylor, W. & Wallis, R. S. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction involving the brain, lung, and lymph nodes. Clin. Infect. Dis. 47, e79–e82 (2008).
Trafford, G. Et al. Anti-TNF therapy for severe CNS tuberculosis causing blindness. Eur. Conf. Clin. Micro. Infect. Dis. [online], (2013).
Wallis, R. S., van Vuuren, C. & Potgieter, S. Adalimumab treatment of life-threatening tuberculosis. Clin. Infect. Dis. 48, 1429–1432 (2009).
St Clair, E. W. Et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1451–1459 (2002).
Maiga, M. Et al. Risk of tuberculosis reactivation with tofacitinib (CP-690550). J. Infect. Dis. 205, 1705–1708 (2012).
Winthrop, K. L. Et al. Tuberculosis and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. Abstr. 64 (Suppl. 10), 1278 (2012).
Sheskin, J. Thalidomide in the treatment of lepra reactions. Clin. Pharmacol. Ther. 6, 303–306 (1965).
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A. & Kaplan, G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173, 699–703 (1991).
Schoeman, J. F., Andronikou, S. & Stefan, D. C., Freeman, N., & van Toorn, R. Tuberculous meningitis-related optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J. Child Neurol. 25, 822–828 (2010).
Schoeman, J. F., Fieggen, G., Seller, N., Mendelson, M. & Hartzenberg, B. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J. Child Neurol. 21, 301–308 (2006).
Schoeman, J. F. Et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J. Child Neurol. 19, 250–257 (2004).
Ito, T. Et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).
Lu, G. Et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305–309 (2014).
Mahony, C. Et al. Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro. Proc. Natl Acad. Sci. USA 110, 12703–12708 (2013).
Koo, M. S. Et al. Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS ONE 6, e17091 (2011).
Subbian, S. Et al. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog. 7, e1002262 (2011).
Maiga, M. Et al. Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment. J. Infect. Dis. 208, 512–519 (2013).
Maiga, M. Et al. Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE 7, e30749 (2012).
Turner, J., Frank, A. A., Brooks, J. V., Marietta, P. M. & Orme, I. M. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 102, 248–253 (2001).
Wallis, R. S. Et al. Pentoxifylline in human immunodeficiency virus-seropositive tuberculosis: a randomized, controlled trial. J. Infect. Dis. 174, 727–733 (1996).
Wallis, R. S. Et al. Pentoxifylline in human immunodeficiency virus–positive tuberculosis: safety at 4 years. J. Infect. Dis. 178, 1861 (1998).
Mayer-Barber, K. D. Et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 511, 99–103 (2014).
Law, K. Et al. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 153, 799–804 (1996).
Fujiwara, H., Kleinhenz, M. E., Wallis, R. S. & Ellner, J. J. Increased interleukin-1 production and monocyte suppressor cell activity associated with human tuberculosis. Am. Rev. Respir. Dis. 133, 73–77 (1986).
Katti, M. K. Assessment of serum IL-1, IL-2 and IFN-γ levels in untreated pulmonary tuberculosis patients: role in pathogenesis. Arch. Med. Res. 42, 199–201 (2011).
Byrne, S. T., Denkin, S. M. & Zhang, Y. Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis. J. Antimicrob. Chemother. 59, 313–316 (2007).
Vilaplana, C. Et al. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J. Infect. Dis. 208, 199–202 (2013).
Lin, H. I., Chu, S. J., Wang, D. & Feng, N. H. Pharmacological modulation of TNF production in macrophages. J. Microbiol. Immunol. Infect. 37, 8–15 (2004).
Ma, S. & Ma, C. C. Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily. Cytokine Growth Factor Rev. 22, 167–175 (2011).
Parihar, S. P. Et al. Statin therapy reduces the Mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation. J. Infect. Dis. 209, 754–763 (2014).
Skerry, C. Et al. Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. J. Antimicrob. Chemother. 69, 2453–2457 (2014).
Kang, Y. A. Et al. The effects of statin use on the development of tuberculosis among patients with diabetes mellitus. Int. J. Tuberc. Lung Dis. 18, 717–724 (2014).
Rajaram, M. V. Et al. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor γ linking mannose receptor recognition to regulation of immune responses. J. Immunol. 185, 929–942 (2010).
Makitalo, L., Rintamaki, H., Tervahartiala, T., Sorsa, T. & Kolho, K. L. Serum MMPs 7–9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease. Scand. J. Gastroenterol. 47, 785–794 (2012).
Caton, J. & Ryan, M. E. Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol. Res. 63, 114–120 (2011).
Walker, N. F. Et al. Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 185, 989–997 (2012).
Skrahin, A. Et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir. Med. 2, 108–122 (2014).